A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

- Lal, Anoushka P., Foong, Yi Chao, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas‑Robledo, Simón, Moghadasi, Abdorreza Naser, Sanfilippo, Paul G., Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan, Alroughani, Raed, Spelman, Tim, Kermode, Allan G., Surcinelli, Andrea, Laureys, Guy, Eichau, Sara, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Hodgkinson, Suzanne, Ramo-Tello, Cristina, Maimone, Davide, Rath, Louise, McCombe, Pamela, Spitaleri, Daniele, Sanchez-Menoyo, Jose Luis, Yetkin, Mehmet Fatih, Baghbanian, Seyed Mohammad, Karabudak, Rana, Al-Asmi, Abdullah, Jakob, Gregor Brecl, Khoury, Samia J., Etemadifar, Masoud, Levitz, David, van Pesch, Vincent, Buzzard, Katherine, Taylor, Bruce, Butzkueven, Helmut, Van der Walt, Anneke, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas

A new era in the treatment of multiple sclerosis

- Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith M., Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.

A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

- Kalincik, Tomas, Jokubaitis, Vilja, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Spelman, Tim, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut, MSBase Study Group,, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

- Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

- Zhu, Chao, Zhou, Zhen, Roos, Izanne, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph

Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation

- Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens

Defining secondary progressive multiple sclerosis

- Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Girard, Marc, Duquette, Pierre, Prat, Alexandre, Lugaresi, Alessandra, Grand'Maison, François, Grammond, Pierre, Hupperts, Raymond, Alroughani, Raed, Sola, Patrizia, Boz, Cavit, Pucci, Eugenio, Lechner-Scott, Jeanette, Bergamaschi, Roberto, Oreja-Guevara, Celia, Iuliano, Gerardo, Van Pesch, Vincent, Granella, Franco, Ramo-Tello, Cristina, Spitaleri, Daniele, Petersen, Thor, Slee, Mark, Verheul, Freek, Ampapa, Radek, Amato, Maria Pia, McCombe, Pamela, Vucic, Steve, Sánchez Menoyo, José Luis, Cristiano, Edgardo, Barnett, Michael H., Hodgkinson, Suzanne, Olascoaga, Javier, Laura Saladino, Maria, Havrdova, Eva, Gray, Orla, Shaw, Cameron, Moore, Fraser, Butzkueven, Helmut, Kalincik, Tomas

Fingolimod after natalizumab and the risk of short-term relapse

- Jokubaitis, Vilija G., Li, Vivien, Barnett, Michael, Grand'Maison, Francois, Trojano, Maria, Slee, Mark, Giuliani, Giorgio, Shaw, Cameron, Boz, Cavit, Spitaleri, Daniele L. A., Verheul, Freek, Haartsen, Jodi, Kalincik, Tomas, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Hodgkinson, Suzanne, Alroughani, Raed, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Duquette, Pierre, Girard, Marc

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

- Tao, Chunrong, Simpson, Steve, Duquette, Pierre, Girard, Marc, Grand'Maison, Francois, Grammond, Pierre, Alroughani, Raed, Terzi, Murat, Oreja-Guevara, Celia, Sajedi, Seyed Aidin, Iuliano, Gerardo, Sola, Patrizia, van der Mei, Ingrid, Lechner-Scott, Jeannette, Van Pesch, Vincent, Pucci, Eugenio, Bergamaschi, Roberto, Barnett, Michael, Ramo, Cristina, Singhal, Bhim, Spitaleri, Daniele L. A., Slee, Mark, Verheul, Freek, Blizzard, Leigh, Fernández Bolaños, Ricardo, Amato, Maria Pia, Cristiano, Edgardo, Granella, Franco, Hodgkinson, Suzanne, Fiol, Marcela, Gray, Orla, McCombe, Pamela, Saladino, Maria Laura, Sánchez Menoyo, José Luis, Havrdova, Eva, Shuey, Neil, Vucic, Steve, Shaw, Cameron, Deri, Norma, Arruda, Walter Oleschko, Butzkueven, Helmut, Spelman, Tim, Taylor, Bruce V., Horakova, Dana, Shaygannejad, Vahid, Lugaresi, Alessandra, Izquierdo, Guillermo, Trojano, Maria

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

- Chan, Andrew, Rose, John, Wright, Katy, Ferraro, Diana, Sola, Patrizia, Hodgkinson, Suzanne, Kalincik, Tomas, Lechner-Scott, Jeanette, McGuigan, Christopher, Spach, Karen, Chen, Chongshu, Fam, Sami, Alvarez, Enrique, Wu, Fan, Miller, Catherine, Bar-Or, Amit, Butzkueven, Helmut, Fox, Robert J., Gold, Ralf, Gudesblatt, Mark, Haartsen, Jodi, Spelman, Tim

Multiple Sclerosis Relapses Following Cessation of Fingolimod

- Malpas, Charles B., Roos, Izanne, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas, MSBase Study Group,, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

- Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette

Prediction of relapse activity when switching to cladribine for multiple sclerosis

- Zhong, Michael, van der Walt, Anneke, Butler, Ernest, Prevost, Julie, Girard, Marc, Oh, Jiwon, Butzkueven, Helmut, Jokubaitis, Vilija, Monif, Mastura, Hodgkinson, Suzanne, Eichau, Sara, Kalincik, Tomas, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Van Pesch, Vincent

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

- Kister, Ilya, Spelman, Tim, Grand'Maison, Francois, Alroughani, Raed, Terzi, Murat, Boz, Cavit, Hupperts, Raymond, Lechner-Scott, Jeannette, Kappos, Ludwig, Pucci, Eugenio, Hodgkinson, Suzanne, Solaro, Claudio, Patti, Francesco, Butzkueven, Helmut, Duquette, Pierre, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy

- Lizak, Nathaniel, Hodgkinson, Suzanne, Butler, Ernest, Lechner-Scott, Jeannette, Slee, Mark, McCombe, Pamela Ann, Shaw, Cameron, Skibina, Olga, Vucic, Steve, Shuey, Neil, Barnett, Michael H., Parratt, John, Butzkueven, Helmut, Jack, Dominic, Fabris, Jessica, Kalincik, Tomas

Response to treatment in NMOSD: the Australasian experience

- Clarke, Laura, Bukhari, Wajih, McCombe, Pamela A., Sutton, Ian, Boggild, Mike, Brownlee, Wallace, Carroll, William M., Hodgkinson, Suzanne, Macdonell, Richard A.L., Mason, Deborah F., Pereira, Jennifer, Slee, Mark, O'Gorman, Cullen M., Das, Chandi, Henderson, APD, Kermode, AG, Lechner-Scott, Jeannette, Waters, P, Sun, J, Broadley, SA, Khalilidehkordi, Elham, Arnett, Simon, Woodhall, Mark, Prain, Kerri M., Parratt, John D.E., Barnett, Michael H., Marriott, Mark P.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

- Kalincik, Tomas, Horakova, Dana, Spelman, Tim, Jokubaitis, Vilija, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Rozsa, Csilla, Grammond, Pierre, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Lechner-Scott, Jeannette, Slee, Mark, Fernandez-Bolanos, Ricardo, Grand'Maison, Francois, Hupperts, Raymond, Verheul, Freek, Hodgkinson, Suzanne

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

- Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy

- Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.